Dupilumab改善儿童哮喘控制与生活质量:VOYAGE研究
VOYAGE研究纳入6-11岁未控制的中重度2型哮喘儿童(n=350),比较dupilumab与安慰剂治疗52周。Dupilumab组ACQ-7-IA评分自第4周起显著改善并持续至52周,更多患儿达到良好控制,儿童及照护者生活质量显著提升。
要点
- Dupilumab在第4周即改善哮喘控制,并持续至52周。
- 第52周Dupilumab组86%达到临床有意义应答,安慰剂组75%。
- 第24周和第52周良好控制比例分别为61%对43%和70%对46%。
核心结论
- 在6-11岁中重度2型哮喘儿童中,dupilumab治疗与快速、持续的哮喘控制改善相关。
- 儿童及照护者的健康相关生活质量均显著改善。
研究设计与样本
- VOYAGE研究为52周治疗期,纳入6-11岁未控制中重度2型哮喘儿童(基线血嗜酸性粒细胞≥150 cells·µL-1或FeNO≥20 ppb;n=350),随机接受dupilumab或安慰剂。
主要发现
- Dupilumab组ACQ-7-IA评分自第4周起显著优于安慰剂,并持续至第52周(第52周最小二乘均值差:-0.44,95%CI -0.59至-0.30;p<0.0001)。
- 第52周达到临床有意义应答(≥0.5分)的比例:dupilumab组86% vs 安慰剂组75%(p=0.0051)。
- 第24周达到良好控制(ACQ-7-IA≤0.75分)的比例:61% vs 43%(p=0.0001);第52周:70% vs 46%(p<0.0001)。
- 第52周PAQLQ(S)-IA和PACQLQ评分均显著改善。
关键数值与推荐
- 哮喘控制评估采用ACQ-7-IA,临床有意义应答定义为改善≥0.5分。
- 良好控制定义为ACQ-7-IA≤0.75分。
- 生活质量评估采用PAQLQ(S)-IA(儿童)和PACQLQ(照护者)。
临床怎么用
- 对于6-11岁未控制的中重度2型哮喘儿童,dupilumab可考虑用于改善哮喘控制和生活质量。
- 治疗早期(第4周)即可评估疗效,并持续至52周。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dupilumab has shown long-term treatment benefits in children with uncontrolled asthma. We assessed in more detail the impact of dupilumab on asthma control and health-related quality of life (HRQoL) in children and their caregivers. METHODS: Children aged 6-11 years with uncontrolled moderate-to-severe type 2 asthma (baseline blood eosinophils ≥150 cells·µL-1 or fractional exhaled nitric oxide ≥20 ppb; n=350) were treated with dupilumab or placebo for 52 weeks in the VOYAGE study. Primary outcomes of these analyses were asthma control (change from baseline in Asthma Control Questionnaire 7 Interviewer-Administered (ACQ-7-IA) and achieving a clinically meaningful response of ≥0.5 points); proportion of patients achieving well-controlled asthma or better (ACQ-7-IA ≤0.75 points); effect on patients' (Standardised Paediatric Asthma Quality of Life Questionnaire Interviewer-Administered (PAQLQ(S)-IA)) and caregivers' (Paediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ)) HRQoL; and allergic rhinitis-related QoL. RESULTS: Dupilumab versus placebo significantly improved children's ACQ-7-IA scores by week 4 with sustained improvements through week 52 (least squares mean difference at week 52: -0.44, 95% CI -0.59- -0.30; p<0.0001); a higher proportion achieved a clinically meaningful response (week 52: 86% versus 75%; p=0.0051). At weeks 24 and 52, more children who received dupilumab achieved well-controlled asthma (ACQ-7-IA ≤0.75 points: 61% versus 43%; p=0.0001 and 70% versus 46%; p<0.0001, respectively). Significant improvements in PAQLQ(S)-IA and PACQLQ scores were observed by week 52. CONCLUSIONS: In children aged 6-11 years with moderate-to-severe type 2 asthma, dupilumab treatment was associated with rapid, sustained improvements in asthma control. HRQoL was significantly improved for children and their caregivers.
引用
- Fiocchi AG, Phipatanakul W, Zeiger RS, et al. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study. Eur Respir J. 2023. PMID: 37734856. doi:10.1183/13993003.00558-2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。